1. Preisler, H.D., Rustum, Y. M.: Prediction of therapeutic response in acute myelocytic leukemia. In: Modern trends in human leukemia III. Neth, R., Hofschneider, P.-H., Mannweiler, K. (eds.), pp. 93–98. Berlin, Heidelberg, New York: Springer 1979
2. Yates, J.W., Wallace, J., Ellison, R.R., Holland, J. F.: Cytosine arabinoside and daunorubicin therapy in acute nonlymphocytic leukemia. Cancer Chemother. Rep. 57, 485–488 (1973)
3. Chang, P., Wiernik, P., Bachur. N., Stoller. R., Chabner, B.: Failure to predict response of acute nonlymphocytic leukemia (ANLL) using assays for deoxycytidine kinase (K) cytidine deaminase (D), and daunorubicin reductase (Red.). Proc. Amer. Soc. Clin. Oncol. 18, 352 (1977)
4. Cassileth, P. A., Katz, M.E.: Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside. Cancer Treat. Rep. 61, 1441–1445 (1977)
5. Omura, G.A., Vogler, W.R., Lynn, M.J.: A controlled clinical trial of chemotherapy vs. BCG immunotherapy vs. no further therapy, in remission maintenance of acute myelogenous leukemia (AML). Proc. Amer. Soc. Clim Oncol. 18, 272 (1977)